Poonacha Kavery Nivana Theethira, Villa Tomás G, Notario Vicente
George Squared Program, College of Science, George Mason University, Manassas, VA 20110, USA.
Department of Microbiology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, 15705 La Coruña, Spain.
Antibiotics (Basel). 2022 Mar 2;11(3):331. doi: 10.3390/antibiotics11030331.
Radiation therapy has been used for more than a century, either alone or in combination with other therapeutic modalities, to treat most types of cancer. On average, radiation therapy is included in the treatment plans for over 50% of all cancer patients, and it is estimated to contribute to about 40% of curative protocols, a success rate that may reach 90%, or higher, for certain tumor types, particularly on patients diagnosed at early disease stages. A growing body of research provides solid support for the existence of bidirectional interaction between radiation exposure and the human microbiota. Radiation treatment causes quantitative and qualitative changes in the gut microbiota composition, often leading to an increased abundance of potentially hazardous or pathogenic microbes and a concomitant decrease in commensal bacteria. In turn, the resulting dysbiotic microbiota becomes an important contributor to worsen the adverse events caused in patients by the inflammatory process triggered by the radiation treatment and a significant determinant of the radiation therapy anti-tumor effectiveness. Antibiotics, which are frequently included as prophylactic agents in cancer treatment protocols to prevent patient infections, may affect the radiation/microbiota interaction through mechanisms involving both their antimicrobial activity, as a mediator of microbiota imbalances, and their dual capacity to act as pro- or anti-tumorigenic effectors and, consequently, as critical determinants of radiation therapy outcomes. In this scenario, it becomes important to introduce the use of probiotics and/or other agents that may stabilize the healthy microbiota before patients are exposed to radiation. Ultimately, newly developed methodologies may facilitate performing personalized microbiota screenings on patients before radiation therapy as an accurate way to identify which antibiotics may be used, if needed, and to inform the overall treatment planning. This review examines currently available data on these issues from the perspective of improving radiation therapy outcomes.
放射治疗已应用了一个多世纪,单独或与其他治疗方式联合使用,以治疗大多数类型的癌症。平均而言,超过50%的癌症患者的治疗计划中包含放射治疗,据估计,放射治疗约占治愈方案的40%,对于某些肿瘤类型,特别是早期疾病阶段诊断的患者,成功率可能达到90%或更高。越来越多的研究为辐射暴露与人类微生物群之间双向相互作用的存在提供了有力支持。放射治疗会导致肠道微生物群组成发生定量和定性变化,通常会导致潜在有害或致病微生物的丰度增加,共生细菌随之减少。反过来,由此产生的失调微生物群成为加剧放射治疗引发的炎症过程给患者带来的不良事件的重要因素,也是放射治疗抗肿瘤效果的重要决定因素。抗生素在癌症治疗方案中经常作为预防感染的药物使用,可能通过其抗菌活性(作为微生物群失衡的介质)以及作为促肿瘤或抗肿瘤效应器的双重能力,从而作为放射治疗结果的关键决定因素,来影响辐射/微生物群的相互作用。在这种情况下,在患者接受辐射之前引入益生菌和/或其他可能稳定健康微生物群的药物变得很重要。最终,新开发的方法可能有助于在放射治疗前对患者进行个性化微生物群筛查,作为一种准确的方法来确定是否需要使用抗生素,并为整体治疗计划提供信息。本综述从改善放射治疗结果的角度审视了目前关于这些问题的现有数据。